Uterine Fibroids and Uterine Thickening: Understanding the Connection

Uterine fibroids (leiomyomas) are benign monoclonal smooth muscle tumors of the myometrium. They are the most common pelvic tumor in women (70–80% by age 50). While fibroids do not directly "cause" endometrial thickening, they alter uterine architecture and hormonal milieu in ways that affect endometrial appearance and function.

Mechanisms Linking Fibroids to Uterine Thickening

1. Global uterine enlargement: Fibroids expand the myometrium → overall uterine volume increases. On imaging, this appears as "thickened" uterine walls.
2. Endometrial distortion: Submucosal fibroids (FIGO Type 0, 1, 2) protrude into the cavity, displacing and compressing endometrium → asymmetric thickness, irregular contour.
3. Altered vascularity: Fibroids recruit blood vessels → increased perfusion → enhanced endometrial proliferation.
4. Hormonal microenvironment: Fibroids express higher estrogen/progesterone receptors and aromatase → local estrogen production → endometrial stimulation.
5. Mechanical signaling: Stretch-induced growth factors (IGF-1, TGF-β, PDGF) from myometrial cells may stimulate endometrial hyperplasia.

Imaging Appearance

• Transvaginal ultrasound: Fibroids = well-circumscribed, hypoechoic/heterogeneous masses. Endometrial thickness measured in sagittal plane; submucosal fibroids may mimic or obscure endometrial line.
• Saline infusion sonohysterography (SIS): Gold standard for cavity contour — distinguishes submucosal fibroids from polyps/hyperplasia.
• MRI: Definitive mapping (FIGO classification), adenomyosis differentiation.

Clinical Significance

• Abnormal uterine bleeding (AUB): Fibroids are leading cause (AUB-L). Mechanism: increased surface area, vascularity, prostaglandins, impaired contractility.
• Infertility/Recurrent loss: Submucosal fibroids distort cavity → implantation failure. Intramural >4 cm may impair perfusion.
• Endometrial hyperplasia/cancer risk: Not directly increased by fibroids, but unopposed estrogen (e.g., PCOS, obesity) drives both. Endometrial sampling if thickened >12 mm (postmenopausal) or abnormal bleeding.

Management

• Asymptomatic: Surveillance (annual US).
• Medical: Tranexamic acid, NSAIDs, OCPs, LNG-IUD (first-line for AUB), GnRH agonists/antagonists (pre-op), SPRMs (ulipristal — restricted).
• Minimally invasive: Hysteroscopic myomectomy (submucosal), UAE, MRgFUS.
• Surgical: Laparoscopic/abdominal myomectomy (fertility preservation), hysterectomy (definitive).

Fibroids reshape the uterus physically and hormonally. "Thickening" on report often reflects fibroid bulk or endometrial distortion—not primary endometrial pathology. Correlation with symptoms and dedicated cavity imaging guides care.